These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16164393)

  • 21. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
    Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
    Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
    Hochberg MC; Lebwohl MG; Plevy SE; Hobbs KF; Yocum DE
    Semin Arthritis Rheum; 2005 Jun; 34(6):819-36. PubMed ID: 15942917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infections associated with tumor necrosis factor-alpha antagonists.
    Crum NF; Lederman ER; Wallace MR
    Medicine (Baltimore); 2005 Sep; 84(5):291-302. PubMed ID: 16148729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.
    Carter JD; Ladhani A; Ricca LR; Valeriano J; Vasey FB
    J Rheumatol; 2009 Mar; 36(3):635-41. PubMed ID: 19132789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2004 Aug; 53(30):683-6. PubMed ID: 15295313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C; Manger B
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
    Weisman MH
    J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
    Wallis RS
    Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.
    Kavanagh PM; Gilmartin JJ; O'Donnell J; O'Flanagan D
    Ir Med J; 2008 Jan; 101(1):6-7. PubMed ID: 18369014
    [No Abstract]   [Full Text] [Related]  

  • 34. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists.
    Hawryluk EB; Linskey KR; Duncan LM; Nazarian RM
    J Cutan Pathol; 2012 May; 39(5):481-92. PubMed ID: 22515220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.